Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05207267
Other study ID # Ling-driving pressure
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 30, 2021
Est. completion date December 30, 2022

Study information

Verified date August 2023
Source Southeast University, China
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective physiologic study, in participants with COVID-19 related or non-COVID-19 related acute respiratory distress syndrome (ARDS) requiring mechanical ventilation less than 48 hours. The investigators assessed the effect of different tidal volume guided by different levels of driving pressure on ventilation inhomogeneity and ventilation/perfusion mismatch by electrical impedance tomography (EIT) in supine and/or prone position.


Description:

Once enrolled, an EIT dedicated belt containing 16 electrodes was placed around the participant's chest at the fifth or sixth intercostal space and connected it to an EIT monitor (PulmoVista 500; Dräger Medical GmbH, Lübeck, Germany). Data were collected in the enrolled day (Day 1),Day 3 and Day 7 including demographic and anthropometric data, a baseline arterial blood gas measurement, and ventilation parameters including type of supplemental oxygen, respiratory rate, fractional concentration of oxygen in inspired air (FiO2). Volume control mode without spontaneous breathing, PEEP will be set according to best respiratory compliance method, and tidal volume (VT) will be set to reach three levels of driving pressure (High 14-15cmH2O, moderate 10-11 cmH2O, and low 7-8 cmH2O). Each level of VT was maintained 10 minutes in supine and/or prone position. In the last minutes of each phase,the participants received instructions of end expiratory occlusion lasting at least 10 seconds and, 1 seconds after the start, a bolus of 10 mL of 10% NaCl solution was injected via the central venous catheter. Clinical data and outcome will be collected.


Recruitment information / eligibility

Status Completed
Enrollment 57
Est. completion date December 30, 2022
Est. primary completion date December 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. aged = 18 years old 2. admitted to intensive care unit with a moderate to severe ARDS 3. invasive mechanical ventilation Exclusion Criteria: 1. contraindications for prone position ventilation 2. Past chronic respiratory diseases (long-term family oxygen therapy for chronic respiratory diseases such as pulmonary fibrosis or COPD) 3. New York Heart Association class above II 4. gave written or witnessed verbal informed consent. 5. Contraindications to the use of EIT (e.g., presence of pacemaker or chest surgical wounds dressing) or prone position (as decided by the attending physician) 6. Impending ECMO (on the basis of clinical judgment, including clinical and physiological parameters).

Study Design


Related Conditions & MeSH terms


Intervention

Device:
driving pressure guided tidal volume
Volume control mode without spontaneous breathing, PEEP will be set according to best respiratory compliance method, and tidal volume (VT) will be set to reach three levels of driving pressure (High 14-15cmH2O, moderate 10-11 cmH2O, and low 7-8 cmH2O). Each level of VT was maintained 10 minutes in supine and/or prone position.

Locations

Country Name City State
China Ling Liu Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Southeast University, China

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary regional compliance using EIT regional compliance using EIT Day 1
Primary regional ventilation regional ventilation using EIT Day 1
Primary regional perfusion regional perfusion using EIT Day 1
Primary Region-ventilation-delay Region-ventilation-delay using EIT Day 1
Primary driving pressure measurement as one index of respiratory compliance Day 3
Primary the number of regional lung ventilation regional ventilation measuring by EIT Day 3
Primary the number of regional lung perfusion regional perfusion measuring by EIT Day 3
Primary the number of region-ventilation-delay (RVD) the RVD measuring by EIT Day 3
Secondary Value of ventilation-perfusion (V/Q) mismatch V/Q mismatch was quantified as the percentage of pixels that were classified as ventilated but not perfused (dead space fraction) plus the percentage of those perfused but not ventilated (shunt fraction). Day 1
Secondary Value of ventilation-perfusion (V/Q) mismatch V/Q mismatch was quantified as the percentage of pixels that were classified as ventilated Day 3
Secondary Value of ventilation-perfusion (V/Q) mismatch V/Q mismatch was quantified as the percentage of pixels that were classified as ventilated Day 7
Secondary The Global Inhomogeneity (GI) index higher values indicating less homogenous ventilation Day 1
Secondary The Global Inhomogeneity (GI) index higher values indicating less homogenous ventilation Day 3
Secondary The Global Inhomogeneity (GI) index higher values indicating less homogenous ventilation Day 7
Secondary Blood gas PaO2 Day 1
Secondary Ventilation free day ventilation free day in day 28 Day 28
Secondary 28 day mortality death in day 28 Day 28
See also
  Status Clinical Trial Phase
Completed NCT04435613 - Clinical and Physiological Assessment of a Nearly Ultra-protective Lung Ventilation Strategy: A Quasi-experimental Preliminary Study in ARDS Patients N/A
Enrolling by invitation NCT05020210 - Effect of Early Treatment With Sivelestat Sodium in ARDS Patients
Completed NCT04468971 - REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia Phase 1
Completed NCT04505592 - Tenecteplase in Patients With COVID-19 Phase 2
Completed NCT04493242 - Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS Phase 2
Withdrawn NCT04909879 - Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome Phase 2
Completed NCT02265198 - Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome N/A
Completed NCT01949272 - Optimization of PEEP for Alveolar Recruitment in ARDS N/A
Not yet recruiting NCT01668368 - Goal Directed Mechanical Ventilation Aimed at Optimal Lung Compliance N/A
Completed NCT01881061 - Lung Sonography in Patients With Acute Respiratory Distress Syndrome in Intensive Care Unit N/A
Completed NCT00808691 - Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit N/A
Completed NCT05035589 - The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
Recruiting NCT04764032 - Right Ventricular Dysfunction in Ventilated Patients With COVID-19
Completed NCT04556513 - Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status
Recruiting NCT06036056 - NMR Based Metabolomics Kinetics in ARDS Patients
Recruiting NCT04503876 - Effects of End-expiratory Positive Pressure Optimization in Intubated Patients With Healthy Lung or Acute Respiratory Distress Syndrome N/A
Recruiting NCT04643691 - Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS Phase 2
Completed NCT04395911 - Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections N/A
Not yet recruiting NCT05341687 - Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in COVID-19 ARDS.
Recruiting NCT05056090 - Effect of Prone Positioning on Mortality in Patients With Mild to Moderate Acute Respiratory Distress Syndrome. N/A